Controlled release technology research article now available online- part 2

Research Article

Journal of Pharmaceutical Sciences
Volume 82 Issue 12, Pages 1292 - 1295
Published Online: 17 Sep 2006
Copyright © 2009 Wiley-Liss, Inc., A Wiley Company
View all previous titles for this journal

Controlled-release isosorbide dinitrate pellets. Part II: In vivo studies
J. K. Lalla *, Shruti U. Bhat, D. M. Girappanavar

Department of Pharmaceutics, Principal K. M. Kundnani College of Pharmacy, Plot No. 47, Dr. R. G. Thadani Marg, Worii Sea Face, Bombay, 400018, India

or Shruti Bhat at http://www.drshrutibhat.com

*Correspondence to J. K. Lalla, Department of Pharmaceutics, Principal K. M. Kundnani College of Pharmacy, Plot No. 47, Dr. R. G. Thadani Marg, Worii Sea Face, Bombay, 400018, India.

Isosorbide dinitrate (ISDN) capsules containing 20.0 and 40.0 mg of the drug (reported earlier in Part I of this series) were evaluated in vivo in eight healthy volunteers in a double-blind study with marketed sustained-release preparations containing 20.0 and 40.0 mg of ISDN. The results were normalized by administering placebo and four conventional ISDN tablets, each containing 5.0 mg of ISDN, to the same group of volunteers in a separate study. The blood pressure of the volunteers was monitored for 8 h. The results indicate that the capsules prepared in the laboratory with the new formulation gave controlled release when compared with the respective marketed SR product.

http://www3.interscience.wiley.com/journal/113293615/abstract